Pharma
Cipla Ltd
CIPLA · NSE · INE059A01026Wednesday, 9 Sept 20263:31 pm
Market Cap—
P/E—
P/B—
EPS—
Div Yield—
ROE11.8%
ROCE14.7%
ROE11.8%
1Y Return-5.50%
Avg. Volume0.8M
Price Chart
52-Week Range
About
Cipla Ltd is a Pharma company listed on NSE.
Technicals
Free account
Register freeTechnicals
Create a free account to view momentum, moving averages, and delivery signals.
Quant
Premium
UpgradeQuant metrics
Upgrade to view volatility, drawdown, factor, and risk metrics.
Key Ratios
Market Cap—
Current Price₹1,368
52W High / Low₹1,673 / ₹1,165.7
Stock P/E—
Price to Book—
EPS (TTM)—
Dividend Yield—
ROE11.8%
1Y Return-5.50%
Day Change-1.15%
Profit & Loss
| Period | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Sales | ₹27,712 Cr | ₹27,145 Cr | ₹25,447 Cr | |
| Expenses | ₹22,866 Cr | ₹21,001 Cr | ₹20,078 Cr | |
| Operating Profit | ₹4,846 Cr | ₹6,144 Cr | ₹5,369 Cr | |
| OPM % | 17.5% | 22.6% | 21.1% | |
| Other Income | ₹73 Cr | ₹55 Cr | ₹81 Cr | |
| Depreciation | ₹1,084 Cr | ₹995 Cr | ₹1,051 Cr | |
| Interest | ₹48 Cr | ₹44 Cr | ₹71 Cr | |
| Profit Before Tax | ₹5,224 Cr | ₹6,821 Cr | ₹5,702 Cr | |
| Tax | ₹1,354 Cr | ₹1,530 Cr | ₹1,547 Cr | |
| Net Profit | ₹3,862 Cr | ₹5,269 Cr | ₹4,154 Cr | |
| EPS (₹) | 48.0 | 65.2 | 51.0 | |
| Dividend Payout % | — | — | — |
Financial history locked
Register freeRegister free to see 1 more year.
Quarterly Results
| Quarter | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Sales | ₹7,077 Cr | ₹6,464 Cr | ₹6,963 Cr | ₹6,837 Cr | |
| Expenses | ₹6,189 Cr | ₹5,850 Cr | ₹5,986 Cr | ₹5,312 Cr | |
| Operating Profit | ₹888 Cr | ₹614 Cr | ₹977 Cr | ₹1,525 Cr | |
| OPM % | 12.6% | 9.5% | 14.0% | 22.3% | |
| Depreciation | — | — | — | — | |
| Interest | ₹17 Cr | ₹13 Cr | ₹14 Cr | ₹14 Cr | |
| Net Profit | ₹786 Cr | ₹543 Cr | ₹674 Cr | ₹1,292 Cr | |
| EPS (₹) | 9.8 | 6.9 | 8.4 | 16.1 |
Quarterly history locked
Register freeRegister free to see 1 more quarter.
Balance Sheet
| Period | FY26 | FY25 | FY24 | FY23 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹162 Cr | ₹162 Cr | ₹161 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹34,270 Cr | ₹31,032 Cr | ₹26,545 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹614 Cr | ₹438 Cr | ₹559 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹7,450 Cr | ₹5,755 Cr | ₹5,452 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹42,496 Cr | ₹37,387 Cr | ₹32,718 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹7,983 Cr | ₹6,705 Cr | ₹6,171 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹112 Cr | ₹140 Cr | ₹130 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | ₹5,620 Cr | ₹5,506 Cr | ₹4,771 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | ₹6,597 Cr | ₹5,642 Cr | ₹5,238 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | ₹1,018 Cr | ₹589 Cr | ₹640 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹21,166 Cr | ₹18,804 Cr | ₹15,768 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹42,496 Cr | ₹37,387 Cr | ₹32,718 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance sheet history locked
Register freeRegister free to see 1 more year.
Cash Flow
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| FY26 | ₹3,940 Cr | ₹-2,326 Cr | ₹-1,234 Cr | ₹380 Cr |
| FY25 | ₹5,005 Cr | ₹-3,691 Cr | ₹-1,293 Cr | ₹21 Cr |
| FY24 | ₹4,134 Cr | ₹-2,988 Cr | ₹-1,200 Cr | ₹-55 Cr |
| FY23 |
Cash flow history locked
Register freeRegister free to see 1 more year.
Peer Comparison
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | — | — | +14.78% | +7.18% |
| Dr Reddys Laboratories Ltd | — | — | +8.84% | -3.74% |
| Apollo Hospitals Enterprise Ltd | — | — | +22.64% | +23.01% |
| Divis Laboratories Ltd | ₹2,50,065 Cr | 83.9 | +16.5% | +46.29% |
| Max Healthcare Institute Ltd | ₹1,00,553 Cr | 67.2 | +14.7% | +0.87% |
Mutual Fund Holdings
Free account
Register freeMutual fund holdings
Create a free account to see institutional ownership snapshots.
Bulk & Block Deals
Free account
Register freeBulk & block deals
Create a free account to view recent institutional deal activity.
Analyst Estimates
Free account
Register freeAnalyst estimates
Create a free account to view analyst estimate summaries.
Latest News
Documents & Filings
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.